MediciNova receives a new patent for MN-166 (ibudilast) in treating chlorine-induced ARDS, valid until 2042.

MediciNova receives Notice of Allowance for a new patent covering MN-166 (ibudilast) for chlorine-induced acute respiratory distress syndrome (ARDS) treatment. The patent, set to expire no earlier than Jan 2042, covers MN-166's use as a monotherapy or in combination with other drugs, and administration methods include oral and intravenous. MediciNova is a NASDAQ-listed biopharmaceutical company with a presence in Tokyo Stock Exchange.